Kirstin Liechty serves as the Senior Director of Clinical Operations at A2 Biotherapeutics, Inc., where she leverages over 20 years of extensive experience in clinical development to drive innovative oncology therapies from concept to clinical reality. Her dynamic leadership spans multiple therapeutic areas, with a...
Kirstin Liechty serves as the Senior Director of Clinical Operations at A2 Biotherapeutics, Inc., where she leverages over 20 years of extensive experience in clinical development to drive innovative oncology therapies from concept to clinical reality. Her dynamic leadership spans multiple therapeutic areas, with a particular emphasis on early-phase oncology trials, where she has successfully guided clinical programs from Pre-IND stages through to FDA approval. Notably, Kirstin has played a pivotal role in overseeing three actively enrolling studies, including two first-in-human products, showcasing her expertise in navigating the complexities of clinical research and regulatory requirements.
In her current role, Kirstin has developed and implemented a robust clinical operations strategy that aligns with the company’s vision for pioneering biotherapeutics. Her strategic oversight has also extended to the management of significant risk companion diagnostic devices, where she contributed to an Investigational Device Exemption (IDE) submission, ensuring compliance with regulatory standards while advancing patient safety and efficacy. Her proficiency in crisis management and regulatory submissions is complemented by her strong foundation in statistical data analysis and drug discovery, making her an invaluable asset in the pharmaceutical industry.
Kirstin’s collaborative approach fosters cross-functional partnerships across clinical operations, data management, biostatistics, medical affairs, and safety, enabling her teams to meet critical milestones efficiently. Her commitment to advancing pediatric hematology/oncology research further underscores her dedication to improving patient outcomes. As she continues to lead at A2 Biotherapeutics, Kirstin remains focused on driving innovation and excellence in clinical operations, ensuring that groundbreaking therapies reach the patients who need them most.
